stockportfolio.pro
Stocks / CNC vs RPRX
CNC vs RPRX
Centene Corporation and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Centene Corporation (CNC) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $32.7B | $31.6B |
| Revenue (latest FY) | $194.78B | $2.38B |
| Net income (latest FY) | $-6.67B | $770.95M |
| Revenue growth (5y CAGR) | 11.9% | 2.3% |
| Net margin | -3.4% | 32.4% |
| Return on equity | -33.4% | 11.9% |
| P/E ratio | — | 28.9 |
| Dividend yield | — | 1.7% |
| Profitable years (of last 10) | 9 | 8 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CNC — free Open RPRX — freeFrequently asked questions
Which is bigger, CNC or RPRX?
Centene Corporation is larger by market capitalization — $32.7B versus $31.6B.
Which grows faster, CNC or RPRX?
Over the last five fiscal years, Centene Corporation grew revenue faster — 11.9%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.